Avet Pharma Announces the Launch of Furosemide for Injection
Eatontown, NJ, December 1, 2014. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Furosemide Injection, USP, in 20mg/2mL, 40mg/4mL and 100mg/10mL strengths. This launch adds to Avet’s growing portfolio of generic injectable products. Furosemide is the AP rated generic equivalent to the diuretic drug Lasix®ⱡ. It is indicated for the treatment of edema. According to IMS data for the twelve-months ended September 2014, the U.S. market for Furosemide injection approximated $28.3 million.